美托洛尔联合曲美他嗪治疗冠心病心力衰竭效果分析

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (29 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical effect of Metoprolol combined with Trimetazidine in the treatment of heart failure of coronary heart disease. Methods A total of 60 patients with heart failure of coronary heart disease admitted to our hospital from January 2015 to January 2018 were selected and divided into the control group and the observation group according to random lottery, 30 cases in each group. Patients in the control group were given routine treatment, while patients in the observation group were given Metoprolol combined with Trimetazidine. The clinical efficacy, left ventricular end-diastolic diameter (LVEDD), left ventricular ejection fraction (LVEF) and left ventricular end systolic diameter (LVESD) were measured and observed before and after treatment in the two groups. Results The clinical total effective rate in the observation group was 93.33%, which was significantly higher than that in the control group (70.00%), and the difference was statistically significant (P＜0.05). Before treatment, there were no significant differences in LVEDD, LVEF and LVESD between the two groups (P＞0.05). After treatment, the level of LVEF of the observation group was significantly higher than that before treatment and the control group, while the level of LVEDD and LVESD of the observation group were significantly lower than those before treatment and the control group, and the difference was statistically significant (P＜0.05). Conclusion Metoprolol combined with Trimetazidine in the treatment of heart failure of coronary heart disease can effectively improve the patient′s heart function, the clinical effect is ideal.

Key words： Metoprolol Trimetazidine Coronary heart disease Heart failure Clinical efficacy

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YU Jie

Cite this article:

YU Jie. Analysis of the effect of Metoprolol combined with Trimetazidine in the treatment of heart failure of coronary heart disease[J]. 中国当代医药, 2019, 26(9): 67-69.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2019/V26/I9/67

[1]	孙小军，卢京.美托洛尔联合曲美他嗪治疗冠心病心力衰竭的临床疗效观察[J].中国医院用药评价与分析，2015，15（3）：312-314.
[2]	李平，李佑美.曲美他嗪联合美托洛尔治疗冠心病心力衰竭对血浆BNP 影响及疗效观察[J].海南医学院学报，2016，22（2）：126-128.
[3]	顾丽萍，胡菁，严蜀华，等.美托洛尔与曲美他嗪治疗老年冠心病心力衰竭的疗效及对患者心功能、心肌重塑和炎症因子的影响[J].中国老年学杂志，2017，37（1）：89-91.
[4]	陶智军.曲美他嗪联合美托洛尔治疗冠心病心力衰竭对血管内皮功能及氧化应激指标的影响[J].中国临床医生杂志，2018，46（6）：667-670.
[5]	施中平，戴海岳.美托洛尔联合曲美他嗪治疗冠心病心力衰竭患者临床疗效观察[J].中国生化药物杂志，2017，37（9）：278-279.
[6]	姜春玲.美托洛尔联合曲美他嗪治疗冠心病心力衰竭的疗效及安全性分析[J].陕西医学杂志，2016，45（8）：1064-1065.
[7]	刘廷怡，刘瑶，王安伟，等.美托洛尔联合曲美他嗪治疗冠心病心力衰竭的临床疗效[J].解放军预防医学杂志，2018，36（6）：713-716.
[8]	姚朝阳.麝香保心丸联合美托洛尔及曲美他嗪治疗冠心病心力衰竭的临床研究[J].中西医结合心脑血管病杂志，2016，14（6）：615-617.
[9]	杨会萍，任骞.美托洛尔联合曲美他嗪对冠心病心力衰竭患者炎性反应、T 细胞亚群及心功能的影响研究[J].实用心脑肺血管病杂志，2016，24（8）：20-23.
[10]	强永在，高喜源.美托洛尔联合曲美他嗪治疗冠心病伴心力衰竭50 例效果观察[J].内蒙古医科大学学报，2018，40（4）：415-416，422.
[11]	黎洁雯.美托洛尔联合曲美他嗪对冠心病心力衰竭病人心脏功能的影响[J].中西医结合心脑血管病杂志，2016，14（21）：2540-2541.
[12]	王学影.曲美他嗪联合琥珀酸美托洛尔治疗冠心病心力衰竭患者的临床效果[J].中国医药导报，2017，14（2）：131-134.
[13]	廖伟明，李海贞.曲美他嗪联合美托洛尔治疗冠心病心力衰竭的临床疗效[J].实用心脑肺血管病杂志，2018，26（Z1）：56-57.
[14]	王盟，张秀芹.曲美他嗪联合琥珀酸美托洛尔治疗冠心病心力衰竭的效果分析[J].中国医学前沿杂志（电子版），2017，9（11）：134-137.
[15]	丁永广.美托洛尔联合曲美他嗪治疗冠心病心力衰竭的临床疗效及其对患者心功能及炎性反应的影响[J].实用心脑肺血管病杂志，2018，26（Z1）：216-217.